Valion Bio, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Valion Bio, Inc. (VBIO) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $133.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-14
- Valion Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $133.00K, a 47.78% increase year-over-year.
- Valion Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $208.00K, a 108.00% increase year-over-year.
- Valion Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $125.00K, a 115.52% increase year-over-year.
- Valion Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $90.00K, a 66.67% increase year-over-year.
- Valion Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $464.00K, a 102.62% increase from fiscal 2024.
- Valion Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $229.00K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $133.00K 10-Q · filed 2026-08-14 | $341.00K derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $208.00K 10-Q · filed 2026-08-14 | |||
| 2025-12-31 | $464.00K 10-K · filed 2026-03-30 | |||
| 2025-09-30 | $125.00K 10-Q · filed 2025-11-14 | $215.00K derived: sum of 2 quarters · filed 2026-08-14 | $315.00K derived: sum of 3 quarters · filed 2026-08-14 | |
| 2025-06-30 | $90.00K 10-Q · filed 2026-08-14 | $190.00K derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $100.00K 10-Q · filed 2026-08-14 | |||
| 2024-12-31 | $229.00K 10-K · filed 2026-03-30 | |||
| 2024-09-30 | $58.00K 10-Q · filed 2025-11-14 | $112.00K derived: sum of 2 quarters · filed 2025-11-14 | $166.00K derived: sum of 3 quarters · filed 2025-11-14 | |
| 2024-06-30 | $54.00K 10-Q · filed 2025-11-14 | $108.00K derived: sum of 2 quarters · filed 2025-11-14 | ||
| 2024-03-31 | $54.00K 10-Q · filed 2025-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |